Another phase I/II clinical trial of breast cancer involves Imx-110, a nanoparticle encapsulating the STAT3/NF-κB/poly-tyrosine kinase inhibitor and doxorubicin (NCT03382340). Here, STAT3 is linked to breast cancer.